Background: The relationship of prostate cancer (PCa) with the presence of catechol-O-methyltransferase (COMT) genetic polymorphism Val158Met (158G/A) has been reported with inconsistent results. The objective of this study was to quantitatively evaluate the association between Val158Met polymorphism and PCa susceptibility. Methods: Two investigators independently searched Medline and the Cochrane Library up to July 18, 2012. Pooled odds ratio and 95% confidence interval were calculated using a fixed or random-effects model. Statistical analysis was performed with Review Manage 5.0 and Stata 11. Results: Of the 7 case-control studies selected for this meta-analysis, a total of 2,292 PCa cases and 2,485 controls were included. The combined results based on all studies suggested that Val158Met was not associated with PCa risk under all genetic models. When stratifying for race, no noteworthy associations were observed in Asians or Caucasians. Conclusion: This meta-analysis suggests that COMT Val158Met polymorphism might not be a risk factor for PCa risk. However, further well-designed studies are required to confirm our findings.

Keywords:
Catechol-O-methyltransferase, Polymorphism, Prostate cancer, Meta-analysis, Association
1.
Bosland MC: The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000;27:39-66.
2.
Bostwick DG, Burke HB, Djakiew D, et al: Human prostate cancer risk factors. Cancer 2004;101:2371-2490.
3.
Shimizu H, Ross RK, Bernstein L, et al: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-966.
4.
Peraldo-Neia C, Migliardi G, Mello-Grand M, et al: Epidermal growth factor receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 2011;11:31.
5.
Magbanua MJ, Sosa EV, Scott JH, et al: Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 2012;12:78.
6.
Grossman MH, Emanuel BS, Budarf ML: Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 1992;12:822-825.
7.
Winqvist R, Lundstrom K, Salminen M, et al: The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenet Cell Genet 1992;59:253-257.
8.
Lundstrom K, Salminen M, Jalanko A, et al: Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 1991;10:181-189.
9.
Zhu BT, Conney AH: Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27.
10.
Cavalieri EL, Stack DE, Devanesan PD, et al: Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997;94:10937-10942.
11.
Cavalieri EL, Devanesan P, Bosland MC, et al: Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 2002;23:329-333.
12.
Lakhani NJ, Sarkar MA, Venitz J, et al: 2- Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165-172.
13.
Ball P, Knuppen R: Catecholoestrogens (2- and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol Suppl (Copenh) 1980;232:1-127.
14.
Yager JD, Liehr JG: Molecular mechanisms of estrogen carcinogenesis. Ann Rev Pharmacol Toxicol 1996;36:203-232.
15.
Miyoshi Y, Noguchi S: Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomed Pharmacother 2003;57:471-481.
16.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
17.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
18.
Omrani MD, Bazargani S, Bagheri M, et al: Association of catechol-O-methyl transferase gene polymorphism with prostate cancer and benign prostatic hyperplasia. J Res Med Sci 2009;14:217-222.
19.
Cussenot O, Azzouzi AR, Nicolaiew N, et al: Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007;25:3596-3602.
20.
Suzuki M, Kurosaki T, Arai T, et al: The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men. Int J Urol 2007;14:800-804.
21.
Low YL, Taylor JI, Grace PB, et al: Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer 2006;56:31-39.
22.
Nock NL, Cicek MS, Li L, et al: Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006;27:1842-1848.
23.
Tanaka Y, Sasaki M, Shiina H, et al: Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:238-244.
24.
Suzuki M, Mamun MR, Hara K, et al: The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur Urol 2005;48:752-759.
25.
Suzuki K, Nakazato H, Matsui H, et al: Genetic polymorphisms of estrogen receptor-α, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 2003;98:1411-1416.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.